HI
CRNX icon

Harbour Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History

Harbour Investments’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37 Buy
+1
New +$37 ﹤0.01% 4692

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbour Investments's CRNX Position: Q2 2026 in Review

Harbour Investments opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 1 share worth $37. The stake represents ﹤0.01% of the portfolio and ranks #4692 among its holdings.

266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Harbour Investments held 1 share of Crinetics Pharmaceuticals worth $37 as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Harbour Investments position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4692 holding.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.